---
schema_version: "secwatch.filing_event.v1"
accession: "0001563665-22-000010"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:08:22.538356+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biostage reports Q3 net loss of $1.1M ($0.10/share); cash runway into Q2 2023

## Summary
- Net loss $1.1M for Q3 2022 vs $0.8M in Q3 2021; EPS -$0.10 vs -$0.08.
- Operating cash $3.0M as of Sept 30, 2022; cash used in ops $3.4M in first 9 months.
- Expects cash to fund operations into Q2 2023.
- Received U.S. patent for cellularized patch-based scaffolds (Biostage Tissue Patch) on Oct 25, 2022.
- Appointed Joseph Damasio as CFO on Aug 8, 2022.

## SEC filing metadata
- accession: 0001563665-22-000010
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000156366522000010/0001563665-22-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000156366522000010/tmb-20221114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001563665-22-000010
- JSON: https://secwatch.observer/filing/0001563665-22-000010.json
- Plain text: https://secwatch.observer/filing/0001563665-22-000010.txt

## Key facts
- Earnings Releases
  Harvard Apparatus Regenerative Technology, Inc. reported the three months ended September 30, 2022 results: net income a net loss of approximately $1.1 million, EPS $0.10 per share.
  - Period: the three months ended September 30, 2022
  - Net income: a net loss of approximately $1.1 million
  - EPS: $0.10 per share
  - Result: reported results
  source text: For the three months ended September 30, 2022, the Company reported a net loss of approximately $1.1 million, or $0.10 per share, compared to a net loss of $0.8 million, or $0.08 per share, for the three months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563665/000156366522000010/0001563665-22-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.